Drugs moving into the clinic: 21
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| Omrix Biopharma- ceuticals & Ethicon (J&J) | Fibrin Patch | Bleeding Magagement (mild to severe) | Aprotinin- free fibrin sealant technology incorporated into Evicel Fibrin Sealant (Human) |
| Cyclacel Pharmaceuticals | CYC116 | Oncology - solid tumours | Aurora kinases A and B, and VEGFR2 inhibitor |
| Biomira | PX-478 | Oncology - multiple tumour types | Hypoxia- inducible factor (HIF)-1 alpha inhibitor |
| NasVax | undisclosed | Anti-infectives & Vaccines - influenza | Flu vaccine using novel adjuvant / delivery system consisting of positively charged polycationic lipid assemblies |
| Nventa Biopharma- ceuticals Corporation | HspE7 and Poly-ICLC | Anti-infectives & Vaccines - human papillomavirus (HPV)-related diseases - Cervical Intraepithelial Neoplasia | DNA technology that covalently fuses heat shock proteins (Hsp) to target antigens, thereby stimulating cellular immune system responses to specific diseases |
| National Institute of Allergy and Infectious Diseases (NIAID) | VRC-AVIDNA036-00-VP | Anti-infectives & Vaccines - influenza | Encodes against the influenza virus H5 haema- gglutinin |
